回复：舒尼替尼治疗转移性肾细胞癌患者的甲状腺功能减退症 - Suppr

Suppr

超能文献

Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

作者信息

Feldman Darren R, Martorella Andrew J, Robbins Richard J, Motzer Robert J

出版信息

J Natl Cancer Inst. 2007 Jun 20;99(12):974-5; author reply 976-7. doi: 10.1093/jnci/djm006. Epub 2007 Jun 12.

DOI:10.1093/jnci/djm006

PMID:17565156

Abstract

摘要

相似文献

Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.回复：舒尼替尼治疗转移性肾细胞癌患者的甲状腺功能减退症

J Natl Cancer Inst. 2007 Jun 20;99(12):974-5; author reply 976-7. doi: 10.1093/jnci/djm006. Epub 2007 Jun 12.

Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.回复：舒尼替尼治疗转移性肾细胞癌患者中的甲状腺功能减退症

J Natl Cancer Inst. 2007 Jun 20;99(12):975-6; author reply 976-7. doi: 10.1093/jnci/djm008. Epub 2007 Jun 12.

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.舒尼替尼治疗的转移性肾细胞癌患者中的甲状腺功能减退症

J Natl Cancer Inst. 2007 Jan 3;99(1):81-3. doi: 10.1093/jnci/djk008.

[Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].[舒尼替尼治疗晚期肾细胞癌患者的甲状腺功能障碍：一个多因素问题]

Endocrinol Nutr. 2010 Dec;57(10):486-91. doi: 10.1016/j.endonu.2010.06.002. Epub 2010 Aug 10.

How does sunitinib cause hypothyroidism?

Thyroid. 2010 Mar;20(3):243-4. doi: 10.1089/thy.2010.1620.

[Treatment with sunitinib and hypothyroidism--a case report and overview of literature].[舒尼替尼治疗与甲状腺功能减退——一例病例报告及文献综述]

Klin Onkol. 2009;22(4):176-8.

Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?服用苹果酸舒尼替尼的转移性肾细胞癌患者中的高脂血症和甲状腺功能减退。相关还是不相关的不良事件？

Clin Genitourin Cancer. 2015 Apr;13(2):e101-5. doi: 10.1016/j.clgc.2014.08.009. Epub 2014 Sep 22.

Sunitinib does not block thyroid peroxidase in patients.舒尼替尼不会阻断患者体内的甲状腺过氧化物酶。

Thyroid. 2014 Aug;24(8):1325-6. doi: 10.1089/thy.2014.0006. Epub 2014 Jun 25.

Unanswered questions regarding the management of sunitinib-induced hypothyroidism.

Nat Clin Pract Oncol. 2007 Dec;4(12):674. doi: 10.1038/ncponc0998. Epub 2007 Oct 23.

Sunitinib induces hypothyroidism with a markedly reduced vascularity.舒尼替尼可导致甲状腺功能减退症，并显著降低血管生成。

Thyroid. 2010 Mar;20(3):323-6. doi: 10.1089/thy.2009.0414.

引用本文的文献

Interactions between thyroid disorders and kidney disease.甲状腺疾病与肾脏疾病之间的相互作用。

Indian J Endocrinol Metab. 2012 Mar;16(2):204-13. doi: 10.4103/2230-8210.93737.

Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.酪氨酸激酶抑制剂引起的甲状腺功能减退症：发病率、病因和治疗。

Target Oncol. 2011 Dec;6(4):217-26. doi: 10.1007/s11523-011-0197-2. Epub 2011 Nov 19.

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.与酪氨酸激酶抑制剂相关的甲状腺功能减退：靶向治疗的一种新出现的毒性作用。

Nat Rev Clin Oncol. 2009 Apr;6(4):219-28. doi: 10.1038/nrclinonc.2009.4.

Drug-induced immune thrombocytopenic purpura secondary to sunitinib.药物性免疫性血小板减少性紫癜继发于舒尼替尼。

Curr Oncol. 2008 Jun;15(3):152-4. doi: 10.3747/co.v15i3.233.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验